Algorithm for Reducing Overall Biological Detriment Caused by PET/CT: an Age-Based Study.
Additional cancer risk
Effective dose
FDG
PET
Radiation risk
Journal
Nuclear medicine and molecular imaging
ISSN: 1869-3474
Titre abrégé: Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101530478
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
25
07
2022
revised:
16
01
2023
accepted:
28
01
2023
medline:
14
5
2023
pubmed:
14
5
2023
entrez:
14
5
2023
Statut:
ppublish
Résumé
This study is to use a simple algorithm based on patient's age to reduce the overall biological detriment associated with PET/CT. A total of 421 consecutive patients (mean age 64 ± 14 years) undergoing PET for various clinical indications were enrolled. For each scan, effective dose (ED in mSv) and additional cancer risk (ACR) were computed both in a reference condition (REF) and after applying an original algorithm (ALGO). The ALGO modified the mean dose of FDG and the PET scan time parameters; indeed, a lower dose and a longer scan time were reported in the younger, while a higher dose and a shorter scan time in the older patients. Moreover, patients were classified by age bracket (18-29, 30-60, and 61-90 years). The ED was 4.57 ± 0.92 mSv in the REF condition. The ACR were 0.020 ± 0.016 and 0.0187 ± 0.013, respectively, in REF and ALGO. The ACR for the REF and ALGO conditions were significantly reduced in males and females, although it was more evident in the latter gender (all Implementation of ALGO protocols in PET can reduce the overall ACR, mainly in young and female patients.
Identifiants
pubmed: 37181801
doi: 10.1007/s13139-023-00788-4
pii: 788
pmc: PMC10172419
doi:
Types de publication
Journal Article
Langues
eng
Pagination
137-144Informations de copyright
© The Author(s) 2023.
Déclaration de conflit d'intérêts
Conflict of InterestMarco Spadafora, Pasqualina Sannino, Luigi Mansi, Ciro Mainolfi, Rosario Capasso, Eugenio Di Giorgio, Salvatore Fiordoro, Serena Imbimbo, Filomena Masone, and Laura Evangelista declare no conflict of interest.
Références
Mayo Clin Proc. 2010 Dec;85(12):1142-6; quiz 1146
pubmed: 21123642
Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1908-1914
pubmed: 29730697
Am J Respir Crit Care Med. 2007 Nov 15;176(10):970-3
pubmed: 17717201
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13761-6
pubmed: 14610281
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2711-2726
pubmed: 34081153
Nucl Med Mol Imaging. 2020 Oct;54(5):224-232
pubmed: 33088351
J Am Coll Cardiol. 2012 Feb 7;59(6):553-65
pubmed: 22300689
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2696-2710
pubmed: 33990846
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):1-4
pubmed: 27695909
BMJ. 2013 May 21;346:f2360
pubmed: 23694687
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Radiology. 2009 Apr;251(1):166-74
pubmed: 19251940
Ann ICRP. 2007;37(2-4):1-332
pubmed: 18082557
Br J Radiol. 2012 Dec;85(1020):e1166-73
pubmed: 23175483
J Nucl Cardiol. 2018 Feb;25(1):39-52
pubmed: 29110288
N Engl J Med. 2007 Nov 29;357(22):2277-84
pubmed: 18046031
J Nucl Med. 2017 Jan;58(1):1-6
pubmed: 27493264
AJR Am J Roentgenol. 2015 Nov;205(5):1026-37
pubmed: 26496550
Mol Imaging Biol. 2018 Apr;20(2):324-335
pubmed: 28721605
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2771-2781
pubmed: 33527176
J Natl Cancer Inst. 2019 Mar 1;111(3):256-263
pubmed: 30020493
Imaging Med. 2009 Oct;1(1):65-84
pubmed: 22308169
Lancet. 2012 Aug 4;380(9840):499-505
pubmed: 22681860
Radiat Prot Dosimetry. 2019 Dec 31;187(2):183-190
pubmed: 31147708
Health Phys. 2016 Mar;110(3):301-4
pubmed: 26808890
NPJ Digit Med. 2021 Aug 23;4(1):127
pubmed: 34426629
J Nucl Med. 2006 May;47(5):885-95
pubmed: 16644760